To learn more about our company's injection molding experts, click here.
Scroll down for more Injection Molding content!
Scroll down for more Injection Molding content!
November 16, 2025
CompoSecure’s planned $5 billion acquisition of Husky Technologies
CompoSecure’s planned $5 billion acquisition of Husky Technologies
CompoSecure’s planned $5 billion acquisition of Husky Technologies marks a significant moment for the plastics processing industry. Husky, headquartered in Bolton, Ontario, has long been recognized as a global leader in injection molding machinery, molds, hot runners, auxiliary systems, and aftermarket services. Its equipment is central to producing everyday plastic products ranging from beverage containers and food packaging to medical devices and consumer electronics.
Founded in 1953, Husky has built a worldwide footprint with more than 30 locations and manufacturing facilities across Canada, the United States, China, India, Luxembourg, and Switzerland. This scale, combined with its technology differentiation, has positioned the company as a trusted partner for processors seeking efficiency, precision, and reliability in polymer manufacturing.
David Cote, former Honeywell CEO and now a backer of CompoSecure, emphasized Husky’s strong industry position during CompoSecure’s Q3 2025 earnings call. He noted that the business aligns with key investment criteria, offering growth opportunities and margin expansion potential. Platinum Equity, Husky’s current owner, echoed this confidence, committing over $1 billion of equity into the transaction.
The acquisition will see Husky continue operating as a standalone business under its existing management team, ensuring continuity for customers and stakeholders. Once finalized in early 2026, the combined enterprise—valued at approximately $7.4 billion—will unite Husky’s plastics processing expertise with CompoSecure’s portfolio of metal payment cards, security, and authentication products. Learn more here.
Founded in 1953, Husky has built a worldwide footprint with more than 30 locations and manufacturing facilities across Canada, the United States, China, India, Luxembourg, and Switzerland. This scale, combined with its technology differentiation, has positioned the company as a trusted partner for processors seeking efficiency, precision, and reliability in polymer manufacturing.
David Cote, former Honeywell CEO and now a backer of CompoSecure, emphasized Husky’s strong industry position during CompoSecure’s Q3 2025 earnings call. He noted that the business aligns with key investment criteria, offering growth opportunities and margin expansion potential. Platinum Equity, Husky’s current owner, echoed this confidence, committing over $1 billion of equity into the transaction.
The acquisition will see Husky continue operating as a standalone business under its existing management team, ensuring continuity for customers and stakeholders. Once finalized in early 2026, the combined enterprise—valued at approximately $7.4 billion—will unite Husky’s plastics processing expertise with CompoSecure’s portfolio of metal payment cards, security, and authentication products. Learn more here.
November 30, 2025
VSC Medical Molding platform Lauches Thanks to Vance Street Capital Acquisition
VSC Medical Molding platform Lauches Thanks to Vance Street Capital Acquisition
Vance Street Capital has taken another decisive step in strengthening its presence in medical manufacturing with the acquisition of Injectech from The West Group. The deal also marks the official launch of the VSC Medical Molding platform, a dedicated portfolio designed to serve the medical device, life science, and bioprocessing markets.
Based in Fort Collins, Colorado, Injectech specializes in custom injection molding and cleanroom assembly of fluid control components. Its product line includes luer locks, tubing connectors, check valves, spikes, and tailored assemblies—critical elements in single-use fluid management systems. By joining forces with VSC Medical Molding, Injectech brings both breadth and depth to the platform’s molding expertise.
The new platform unites Injectech with two earlier acquisitions: Plastic Design Company (PDC), acquired in 2021, and Resenex, added in 2024. PDC is known for precision injection molding and advanced assembly, particularly with complex materials such as PEEK and cyclic olefin polymers. Resenex complements this with high-flow check valves and specialized connectors, further diversifying the molding portfolio.
Jeff Kyle, CEO of VSC Medical Molding, emphasized the strategic fit: combining Injectech’s extensive component portfolio with in-house tooling and precision molding capabilities enhances the ability to deliver specialized solutions across critical applications.
The timing is significant. Contract manufacturing for medical device OEMs is projected to grow at an annual rate of 11.89% through 2032, rising from $69.75 billion in 2023 to $191.40 billion. Learn more about this topic here.
Based in Fort Collins, Colorado, Injectech specializes in custom injection molding and cleanroom assembly of fluid control components. Its product line includes luer locks, tubing connectors, check valves, spikes, and tailored assemblies—critical elements in single-use fluid management systems. By joining forces with VSC Medical Molding, Injectech brings both breadth and depth to the platform’s molding expertise.
The new platform unites Injectech with two earlier acquisitions: Plastic Design Company (PDC), acquired in 2021, and Resenex, added in 2024. PDC is known for precision injection molding and advanced assembly, particularly with complex materials such as PEEK and cyclic olefin polymers. Resenex complements this with high-flow check valves and specialized connectors, further diversifying the molding portfolio.
Jeff Kyle, CEO of VSC Medical Molding, emphasized the strategic fit: combining Injectech’s extensive component portfolio with in-house tooling and precision molding capabilities enhances the ability to deliver specialized solutions across critical applications.
The timing is significant. Contract manufacturing for medical device OEMs is projected to grow at an annual rate of 11.89% through 2032, rising from $69.75 billion in 2023 to $191.40 billion. Learn more about this topic here.
© Copyright Bryan Hauger Consulting Inc. 2014-2025 All rights reserved.